ACADIA RADIANT (Alzheimer’s Disease Psychosis)
In this study, researchers will evaluate ACP-204 in patients with Alzheimer’s Disease Psychosis.
Inclusion Criteria:
- 50 years to 95 years of age
- Meets clinical criteria for possible or probable Alzheimer’s Disease
- Psychotic symptoms (hallucinations or delusions) for at least 2 months
- Availability of a designated study partner/caregiver
What to Expect
Participants will receive either ACP-204 or a placebo as an oral medication. A placebo looks like the study drug but contains no real medicine. After 6 weeks, participants may have the opportunity to enroll in an open-label extension study, where ACP-204 will be administered.
For more information click the link below or contact Tiffany Hoefler at thoefler@dentinstitute.com or 716-961-9219
Subscribe To Our Newsletter
Sign up to receive email updates on announcements, new services added, company updates & more!
Want to participate in a study?
Fill out the form below and one of our Research Coordinators will be in contact with you as soon as possible. If we currently do not have a study that is currently available for you, we will add you to our database for future studies.